Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Double-blind, Randomized, Comparative Immunogenicity and Safety Trial of Flu-M [Inactivated Split Influenza Vaccine], Solution for Intramuscular Injection, 0.5 ml (FSUE SPbSRIVS FMBA), vs. Ultrix®, Solution for Intramuscular Injection, 0.5 ml (FORT LLC) in Volunteers Aged Over 60 Years

NCT05089123 is registered in ClinicalTrials.gov with St. Petersburg Research Institute of Vaccines and Sera as lead sponsor.

NCT NCT05089123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05089123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Double-blind, Randomized, Comparative Immunogenicity and Safety Trial of Flu-M [Inactivated Split Influenza Vaccine], Solution for Intramuscular Injection, 0.5 ml (FSUE SPbSRIVS FMBA), vs. Ultrix®, Solution for Intramuscular Injection, 0.5 ml (FORT LLC) in Volunteers Aged Over 60 Years
Lead sponsor
St. Petersburg Research Institute of Vaccines and Sera
Phase
Phase 3
Overall status
Completed
Start date
March 3, 2020
Completion date
August 24, 2020
Enrollment
320 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza